Tawanda Gumbo, MD

CEO
Praedicare Inc.

Disclosure(s): Hydronium Biopharma: Ownership Interest, Stocks/Bonds; Praedicare Africa Pvt Ltd: Board Member, Ownership Interest, Stocks/Bonds; Praedicare Inc.: Ownership Interest, Patents, Stocks/Bonds

Tawanda Gumbo, MD, is Presiednt & CEO of Praedicare Inc., and founder of Praedicare Africa PVT LTD.Praedicare Inc is an end-to-end drug development company, from drug discovery to phase IV trials, that uses preclinical wet lab models mathematically mapped to patients for quantitative prediction of clinical trial outcomes, significantly reducing clients’ risk, time, and costs of developing safe and effective new drugs. Praedicare Africa, in 28 African countries, is the first fully-capable CRO to offer customized end to end drug development solutions andcommercialization services across the African continent.

Poster(s):

• 1697 - Dose-response Studies of the Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, Epetraborole, in the Intracellular Hollow Fiber System Model of Mycobacterium avium complex Lung Disease
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1698 - Pharmacokinetics/pharmacodynamics of Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, and High Intracellular Penetration in the Intracellular Hollow Fiber System Model of Mycobacterium avium Complex Lung Disease
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET